rs119466002
Variant summary
Our verdict is Pathogenic. The variant received 11 ACMG points: 11P and 0B. PP2PP3_ModeratePP5_Very_Strong
The NM_176824.3(BBS7):c.632C>T(p.Thr211Ile) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000124 in 1,612,292 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. T211A) has been classified as Uncertain significance.
Frequency
Consequence
NM_176824.3 missense
Scores
Clinical Significance
Conservation
Publications
- Bardet-Biedl syndrome 7Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae), Genomics England PanelApp
- ciliopathyInheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
- Bardet-Biedl syndromeInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 11 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| BBS7 | NM_176824.3 | c.632C>T | p.Thr211Ile | missense_variant | Exon 7 of 19 | ENST00000264499.9 | NP_789794.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000592 AC: 9AN: 152006Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.00000796 AC: 2AN: 251334 AF XY: 0.0000147 show subpopulations
GnomAD4 exome AF: 0.00000753 AC: 11AN: 1460286Hom.: 0 Cov.: 30 AF XY: 0.00000826 AC XY: 6AN XY: 726454 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000592 AC: 9AN: 152006Hom.: 0 Cov.: 32 AF XY: 0.0000943 AC XY: 7AN XY: 74262 show subpopulations
ClinVar
Submissions by phenotype
Bardet-Biedl syndrome 7 Pathogenic:2
BBS7-related disorder Pathogenic:1
The BBS7 c.632C>T variant is predicted to result in the amino acid substitution p.Thr211Ile. This variant has been reported to be causative for Bardet-Biedl syndrome due to a dominant-negative effect (Badano et al. 2003. PubMed ID: 12567324; Zaghloul et al. 2010. PubMed ID: 20498079; Chen et al. 2011. PubMed ID: 21642631). This variant is reported in 0.00088% of alleles in individuals of European (Non-Finnish) descent in gnomAD. This variant is interpreted as pathogenic.
Bardet-Biedl syndrome 1/7, digenic Pathogenic:1
Bardet-Biedl syndrome Pathogenic:1
This sequence change replaces threonine, which is neutral and polar, with isoleucine, which is neutral and non-polar, at codon 211 of the BBS7 protein (p.Thr211Ile). This variant is present in population databases (rs119466002, gnomAD 0.0009%). This missense change has been observed in individual(s) with Bardet-Biedl syndrome (PMID: 12567324, 21642631). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 3016). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt BBS7 protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects BBS7 function (PMID: 20498079, 22500027, 23572516). For these reasons, this variant has been classified as Pathogenic.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at